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 Patient: Female, 52
 Final Diagnosis: Brain abscess
 Symptoms: Fever • headache • weakness, left sided
 Medication: Prednisolone • Azathioprine • Rituximab
 Clinical Procedure: Stereotactic brain biopsy and LP
 Specialty: Neurology
 Objective: Rare disease
 Background: Immunocompromised patients are at increased risk for developing meningitis or, rarely, brain abscess with op-
portunistic organisms like Listeria monocytogenes.
 Case Report: A 52 year-old Saudi Arabian woman who was diagnosed with pemphigus vulgaris and diabetes and had been 
on prednisolone and azathioprine for about 4 years. She presented with headache, low-grade fever, and left-
sided weakness 2 weeks after receiving the second dose of rituximab infusion. Magnetic resonance imaging 
revealed an enhanced space-occupying lesion with multiple small cyst-like structures and vasogenic edema in 
the right temporoparietal area. Her blood culture was positive for Listeria monocytogenes, and a brain biopsy 
showed necrotic tissues with pus and inflammatory cells. She recovered after a 6-week course of antibiotics 
with ampicillin and gentamycin.
 Conclusions: Brain abscess due to Listeria monocytogenes is a risk that should be considered when adding rituximab to the 
regimen of a patient who is already Immunocompromised.
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Background
The gram-positive bacillus Listeria monocytogenes (LM) is an 
opportunistic pathogen that can invade the central nervous 
system (CNS) and cause severe infections. The most common 
CNS manifestations of listeriosis are meningitis, meningoen-
cephalitis, and, rarely, brain abscess [1]. Neonates, pregnant 
women, elderly, and immunocompromised individuals are par-
ticularly vulnerable to developing CNS listeriosis [2].
Rituximab (RTX) is a monoclonal anti-CD20 antibody that in-
duces B cell depletion (2) and has been widely used for the 
treatment of follicular non-Hodgkin’s lymphoma and several 
autoimmune disorders, including resistant cases of pemphi-
gus vulgaris (PV) [3].
To our knowledge there have been no reported cases of lis-
terial brain abscesses in patients treated with RTX. Here, we 
describe a patient with PV who developed a right temporopa-
rietal brain abscess shortly after RTX was added to an exist-
ing regimen of corticosteroid and azathioprine.
Case Report
A 52-year-old Saudi Arabian woman presented to our hospital 
with low-grade fever, severe headache, and progressive left-sid-
ed weakness with numbness; she had developed these symp-
toms 5 days earlier following a second RTX infusion that was 
initiated 2 weeks earlier to treat PV. She had underlying type II 
diabetes mellitus, hypertension, and hypothyroidism, which she 
acquired during a course of corticosteroid therapy. She was tak-
ing prednisolone (60 mg once daily), azathioprine (250 mg once 
daily), simvastatin, atenolol, and chloroquine. On examination, 
her temperature was 38°C, blood pressure was 146/82 mmHg, 
pulse rate was 105 bpm, and her respiratory rate was 22/min-
ute. The patient was obese, with a body mass index of 37.7, 
and she had a cushingoid appearance. She was lethargic but 
able to follow commands. Neurological examination revealed a 
gaze preference to the right, spastic tone, and hyperreflexia on 
her left side, with motor strength of 3/5 on the left and 5/5 on 
the right using the Medical Research Council (MRC) scale. Her 
plantar reflexes exhibited an extensor response on the left. No 
neck stiffness was detected. A complete blood count showed 
a hemoglobin level of 11.8 g/dL with a white blood cell count 
(WBC) of 8.0×109/L (neutrophils 82%, lymphocytes 7%, and 
monocytes 11%). The test for HIV was negative and her toxo-
plasma IgM titre was 0.00 and nonreactive for IgG. Computed 
tomography (CT) of the brain after contrast material adminis-
tration revealed a hypodense lesion with abnormal enhance-
ment of the right temporoparietal lobe with surrounding vaso-
genic brain edema and no midline shift. She was admitted to 
the medical ward with a tentative diagnosis of brain abscess, 
and empirical intravenous antibiotic treatment with vancomy-
cin and meropenem was initiated. Brain magnetic resonance 
imaging (MRI) showed right temporoparietal enhancement with 
a central area of restricted diffusion representing multiple tiny 
abscesses with vasogenic edema (Figure 1). A lumbar punc-
ture was performed on the same day, and her cerebrospinal 
fluid (CSF) contained 113 WBCs, predominantly lymphocytes, 
393 red blood cells, and a high protein level 0.66 g/L. The CSF 
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Figure 1.  Brain MRI, next day of presentation to the emergency 
room. (A) Preoperative MRI scan, T2 coronal window, 
showing a large abscess in the right temporal lobe 
surrounded by extensive vasogenic edema. (B) MRI 
of the brain, T1 weighted images with gadolinium, 
coronal window showing multiple abscesses in the 
right temporal.
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and serum levels of glucose were 3.0 and 8.0 mmol/L, respec-
tively. Two tubes of blood for aerobic and nonaerobic culture 
were collected upon her presentation in the emergency room 
and before initiation of antimicrobial therapy. Subsequently, 
her prednisolone dose was tapered down gradually, and her 
azathioprine dose was reduced to 150 mg daily. Because of 
the failure to improve with empirical antibiotic therapy, on the 
second week of her admission she underwent a stereotactic 
brain biopsy. It revealed acute inflammatory cells, necrotic tis-
sues debris, and macrophages, which indicated an infection al-
though the tissue culture was negative. By that time, LM grew 
up on both tubes of the blood culture. According to the result 
of organism sensitivity, her antibiotics were adjusted to ampi-
cillin (2 g every 4 hours for 6 weeks), administered in combi-
nation with adjuvant  intravenous gentamicin (120 mg every 8 
hours for 6 weeks). Her weakness abated within 2 weeks, and 
she was able to walk with unilateral support. A follow-up MRI 
of the brain after 4 months of treatment showed nearly com-
plete resolution of the lesion, with residual hypodensity at the 
site of the abscess evacuation and no contrast enhancement 
of the right temporoparietal region (Figure 2).
Discussion
LM is a gram-positive, facultative, anaerobic, non-spore-forming 
rod. The organism is widely spread throughout the environment 
and can be found in soil and water, as well as in plants and ani-
mals commonly used for human consumption [4]. The principal 
route of transmission in humans is through the ingestion of con-
taminated food. Normally, the organism is rapidly cleared from 
the gastrointestinal tract. Alternatively, LM may cause illness 
after an incubation period of 11–71 days (median 31 days) [5].
LM is an uncommon cause of illness in the general popula-
tion, but it can cause life-threatening infections in neonates, 
pregnant women, the elderly, and immunosuppressed pa-
tients. Protection against LM is predominantly cell-mediat-
ed [6]; therefore, conditions associated with impaired cellular 
immunity are risk factors for LM infection [7]. Rituximab de-
pletes B cells, but in vitro studies have demonstrated that B 
cells are necessary for the induction of optimal CD4 memo-
ry [8]. Therefore, while rituximab directly impairs humoral im-
munity, it also has downstream effects on cellular immunity.
Meningitis is the most common CNS infection caused by LM 
[1], and brainstem encephalitis (rhombencephalitis) is also well 
recognized [9]. Brain abscess accounts for approximately 10% 
of CNS with LM infections [1]. LM brain abscesses are usually 
reported as an infectious complication in immunosuppressed 
patients and are commonly associated with positive blood cul-
ture in 85% of patients while concomitant meningitis in near-
ly 25% of patients [10]. The high rate of positive blood culture 
results suggest that the pathogenesis of Listeria brain abscess 
is secondary to hematogenous spread.
A recent review found that 56 cases of macroscopic brain ab-
scesses due to L. monocytogenes have been reported between 
1968 and 2011. Most patients (80%) had underlying conditions, 
such as a hematological malignancy (23%), autoimmune diseases 
treated with prednisolone (19%), having undergone solid organ 
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Figure 2.  Brain MRI 4 months, post treatment. (A) MRI, T2 
weighted image, coronal window, showing residual 
low signal intensity, gliosis and atrophy on the right 
temporal lobe. (B) MRI, T1 coronal window post 
contrast, showing right temporal low signal intensity, 
gliosis and atrophy with no contrast enhancement.
67
Al-Harbi T.M. et al.: 
Brain abscess following Rituximab infusion in a patient with pemphigus vulgaris
© Am J Case Rep, 2015; 16: 65-68
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported License
transplant (10%), diabetes mellitus (12%), human immunodefi-
ciency virus (HIV) infection (7%), or others (9%). Positive blood 
cultures and CSF cultures were found in 79% and 23%, respec-
tively. Ampicillin-based regimens were used in 37 patients (74%). 
Twenty-nine patients (51%) underwent surgery. A total of 19 
patients died, giving a mortality rate of 33%. Patients who had 
underlying diseases and who did not undergo surgical interven-
tions were more likely to die (63% and 74%, respectively) [2].
This patient presented with headache, fever, lethargy, and left-
sided weakness; a combination of symptoms highly suggestive 
of CNS infection with space-occupying lesion-like pyogenic brain 
abscess. Infections with mycobacterium tuberculosis and toxo-
plasmosis were also considered due her immunosuppressed 
state. Primary CNS tumors and metastasis were also included in 
her differential diagnosis prior to the result of the blood culture.
In our patient, there was a strong temporal relationship be-
tween RTX treatment and the onset of neurologic symptoms, 
suggesting that RTX played a decisive role in the development 
of this opportunistic infection. RTX is a potent immunosuppres-
sive medication that induces rapid and long-lasting depletion of 
circulating B cells. Indeed, although the patient had been using 
corticosteroids and azathioprine for several years, a cerebral 
abscess only developed after the initiation of RTX infusions.
While RTX is usually well tolerated, it poses the risk of oppor-
tunistic infections in at-risk patients, possibly because it in-
duces hypogammaglobulinemia and causes delayed-onset 
neutropenia [11].
While Listeria abscess has not been reported previously follow-
ing rituximab therapy, other similar, infrequent opportunistic 
neurological complications have been documented. Charles et 
al. [12] described a right frontal brain abscess due to Legionella 
micdadei in a 59-year-old man with Waldenström’s macro-
globulinemia who had completed a 6-month course of che-
motherapy with RTX and a DNA synthesis inhibitor (fludara-
bine) 6 weeks prior to his initial presentation with recurrent 
falls, aphasia, confusion, and hallucinations [12].
Enteroviral meningoencephalitis following RTX therapy was 
also reported in a child with autoimmune thrombocytope-
nia and an adult patient with relapsed B cell lymphoma [13]. 
In another report, reactivation of cerebral toxoplasmosis af-
ter RTX therapy in a 71-year-old female with cutaneous vas-
culitis associated with type I cryoglobulinemia was described 
[14]. Furthermore, a recent study found 57 cases of progres-
sive multifocal leukoencephalopathy associated with RTX use 
in HIV-negative patients; 90% of the patients had lymphopro-
liferative disorders, and 4 patients with rheumatoid arthritis 
were described in a separate cases series [15,16].
Conclusions
Adding RTX to an immunosuppressive medication regimen 
may increase the risk of a rare brain infection like LM, which 
can cause brain abscesses; therefore, close monitoring of pa-
tients who receive RTX is highly recommended.
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